Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553319/0/en/Portage-Biotech-Presents-Updated-Data-on-the-Phase-1-2-Trial-Evaluating-PORT-2-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-37th-Annual-Meeting.html

WESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the presentation of updates from its ongoing Phase 1/2 study of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) agonist for patients with non-small cell lung cancer (NSCLC) and advanced melanoma, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022). The meeting is being held from November 8-12 in Boston, Massachusetts.

Read more at globenewswire.com

Related news for (PRTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.